prognostic significance. A large prospective multiinstitutional validation study is required to confirm our results.

ACKNOWLEDGMENTS

The authors thank Hiroaki Akamatsu, MD, Satoru Miura, MD, Madoka Kimura, MD, Rieko Kaira, MD, Sakae Morii, MD, Chikara Sakaguchi, MD, Hirofumi Eida, MD, Yoko Toda, MD, and Akihiro Tamiya, MD, for their constructive advice and provision of patients for this study.

REFERENCES

1. Jackman DM, Johnson BE. Small-cell lung cancer. *Lancet* 2005;366: 1385–1396.
2. Krug LM, Kris MG, Travis WD. Small cell and other neuroendocrine tumors of the lung. In DeVita VT, Lawrence TS, Rosenberg SA (Eds.). CANCER Principles and Practice of Oncology, 8th Ed. Philadelphia: Lipponcott Willams & Wilkins, 2008. Pp. 946–963.
3. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004;10:6897–6904.
4. Fetsch PA, Cowan KH, Weng DE, et al. Detection of circulating tumor cells and micrometastases in stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry. *Diagn Cytopathol* 2000; 22:323–328.
5. Loberg RD, Fridman Y, Pienta BA, et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. *Neoplasia* 2004; 6:302–309.
6. Molnar B, Sipos F, Galamb O, et al. Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. *Dig Dis* 2003;21:320–325.
7. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004;351:781–791.
8. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. *Clin Cancer Res* 2009;15: 6980–6986.
9. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. *J Clin Ligand Assay* 2002;25:104–110.
10. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. *Clin Cancer Res* 2007;13: 920–928.
11. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:3213–3221.
12. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. *Ann Oncol* 2009;20:1223–1229.
13. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. *J Clin Oncol* 2005;23:1420–1430.
14. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008;14:6302–6309.
15. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. *J Clin Oncol* 2011;29:1556–1563.
16. Hou JM, Greystoke A, Lancashire L, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. *Am J Pathol* 2009;175:808–816.
17. Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. *J Thorac Oncol* 2009;4:30–36.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.
19. Kularatne BY, Lorigan P, Browne S, et al. Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. *Cytometry* 2002;50:160–167.
20. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. *Lancet Oncol* 2009;10:233–239.
21. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. *J Clin Oncol* 2008;26:5401–5406.
22. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17:658–667.
23. Puglisi M, Dolly S, Faria A, et al. Treatment options for small cell lung cancer - do we have more choice? *Br J Cancer* 2010;102:629–638.
24. Nisman B, Biran H, Ramu N, et al. The diagnostic and prognostic value of ProGRP in lung cancer. *Anticancer Res* 2009;29:4827–4832.
25. Wójcik E, Kulpa JK, Sas-Korczyńska B, et al. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. *Anticancer Res* 2008;28:3027–3033.
26. Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). *Lung Cancer* 2001;32:61–69.
27. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. *J Clin Oncol* 1991;9:1618–1626.
28. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. *J Clin Oncol* 2009;27:5153–5159.
29. Lin H, Balic M, Zheng S, et al. Disseminated and circulating tumor cells: role in effective cancer management. *Crit Rev Oncol Hematol* 2011;77: 1–11.
30. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. *Cancer Biol Ther* 2007;6:308–312.
31. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. *J Clin Oncol* 2011;29:1508–1511.
32. Fehm T, Muller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. *Breast Cancer Res Treat* 2010;124:403–412.
33. Ignatiadis M, Rothe F, Chaboteaux C, et al. HER2-positive circulating tumor cells in breast cancer. *PLoS One* 2011;6: e15624.
34. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. *Clin Cancer Res* 2010;16:2634–2645.
35. Jiang Y, Palma JF, Agus DB, et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. *Clin Chem* 2010;56:1492–1495.
36. Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. *Clin Cancer Res* 2009;15:2091–2097.
37. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. *N Engl J Med* 2008;359:366–377.
38. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 2007; 450:1235–1239.

Copyright © 2012 by the International Association for the Study of Lung Cancer

Copyright © 2012 by the International Association for the Study of Lung Cancer.

Med Oncol (2012) 29:215–218
DOI 10.1007/s12032-010-9801-z

ORIGINAL PAPER

Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer

Motohiro Tamiya · Hidekazu Suzuki · Masashi Kobayashi · Shinji Sasada · Norio Okamoto · Naoko Morishita · Tomomi Yasue · Yuka Matsuura · Tomonori Hirashima · Ichiro Kawase

Received: 18 December 2010 / Accepted: 22 December 2010 / Published online: 22 January 2011
© Springer Science+Business Media, LLC 2011

Abstract Bone metastasis is an important factor for determining the appropriate treatment for patients with lung cancer. The cross-linked N-terminal telopeptide of type I collagen (NTx) is a metabolite of type I collagen, the main constituent of the bone matrix. Urinary NTx is recognized as a useful marker of bone metastasis, but the application of serum NTx and its cutoff value for determining bone metastasis from lung cancer have not been characterized. We measured serum NTx by enzyme-linked immunosorbent assay of individuals who underwent staging during hospitalization for initial treatment of lung cancer in our department and compared the NTx levels with the presence of bone metastasis in staging. The study included 166 patients with lung cancer (128 men and 38 women), including 85 adenocarcinoma, 42 squamous cell carcinoma, 32 small-cell carcinoma, and 7 other cancer types. Bone metastasis was present in 73 cases. The average/median serum NTx of bone metastasis (+) and bone metastasis (−) was 27.8/23.8 and 17.1/16.5 nmol bone collagen equivalents/L, respectively. There was an intentional difference with $P < 0.001$. The cutoff value of the serum NTx level indicating bone metastasis from lung cancer was estimated using the receiver operating characteristics curve. The optimal cutoff value was found to be 22.0 (sensitivity: 61.6%, specificity: 89.2%). The results of univariate and multivariate analysis revealed that the serum NTx levels were significantly related to bone metastasis from lung cancer ($P < 0.001$). Measurement of serum NTx levels provides a simple diagnostic marker of bone metastasis from lung cancer.

Keywords Cross-linked N-telopeptide of type I collagen · Bone metastasis · NTx · Lung cancer

M. Tamiya (✉) · H. Suzuki · M. Kobayashi · S. Sasada · N. Okamoto · N. Morishita · Y. Matsuura · T. Hirashima · I. Kawase
Department of Thoracic Malignancy, Osaka Prefectural Hospital Organization, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino 3-7-1, Habikino, Osaka 583-8588, Japan
e-mail: moto19781205@yahoo.co.jp

T. Yasue
Department of Laboratory Medicine, Osaka Prefectural Hospital Organization, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino 3-7-1, Habikino, Osaka 583-8588, Japan

Introduction

Lung cancer is the leading cause of cancer-related deaths in Japan and several other countries. Bone metastasis is one of the most common complications of cancer metastasis, particularly in lung, breast, and prostate cancer, with rates of 30–60, 73, and 68%, respectively [1, 2]. Bone metastasis is an important factor that guides the selection of the most appropriate treatment for patients with lung cancer, and as a result, it affects the prognosis as well as the patients' quality of life.

Bone metastasis is primarily evaluated using bone scintigraphy, bone radiography, and magnetic resonance imaging (MRI). More recently, ^{18}F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been used for further evaluation. Although bone scintigraphy has high sensitivity, its specificity is inadequate due to false-positive results caused by inflammation and traumatic fractures [3, 4]. Furthermore, MRI and FDG-PET are costly and time-consuming. Therefore, we sought to identify a diagnostic marker of bone metastasis for convenient clinical use.

A number of studies have evaluated the urine and blood levels of bone biochemical markers, including urinary deoxypyridinoline (D-PYD), serum pyridinoline cross-linked C-telopeptide of type I collagen (1CTP), and urinary pyridinoline cross-linked N-telopeptide of type I collagen (NTx). It has been demonstrated that these molecules are useful as markers for detecting bone metastasis by various cancers [5–7]. However, an appropriate serum NTx level and cutoff value for the determination of bone metastasis from lung cancer have not been defined. In this study, we determined the cutoff value of the serum NTx for bone metastasis from lung cancer and investigated the relationship between baseline serum NTx levels and bone metastasis from patients with lung cancer.

Patients and methods

The subjects included 166 patients who underwent staging for the initial treatment of lung cancer during hospitalization in our department between September 2008 and September 2010. For each patient, a blood specimen for the assessment of serum NTx levels was collected early in the morning on the day after admission. For comparison, serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), calcium (Ca), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYF), neuron-specific enolase (NSE), blood urea nitrogen (BUN), creatinine (Cr), total protein (TP), and albumin (ALB) were simultaneously measured. We excluded patients with poor renal function, for which the eGFR (estimated glomerular filtration rate) value at the time was estimated to be 60 mL/min or less. The serum NTx level was measured by ELISA.

Bone scintigraphy was used to determine the presence or absence of bone metastasis. When it was necessary to obtain a more detailed evaluation for bone metastasis, we added contrast-enhanced computed tomography (CT) from the thorax to pelvis, MRI, and FDG-PET.

The "R, ver2.8.1" software program (available at: http://www.R-project.org; R Foundation for Statistical Computing, Vienna, Austria) was used to perform the analysis. The optimal cutoff value was selected by performing a receiver operating characteristic (ROC) curve analysis of relationship between abnormal serum NTx values and bone metastasis from lung cancer, and its cutoff value was used for the evaluations in the subsequent analyses. Univariate and multivariate analyses were performed using a logistic regression. Only the variables that were found to have a p value of less than 0.10 in univariate analysis were included in the multiple logistic regression analysis. These variables included performance status (PS), ALB, Ca, ALP, LDH, and NTx. A p value of less than 0.05 was considered statistically significant.

Results

A total of 166 patients (128 men and 38 women) were included in the study. The median age was 68 years (range: 23–85 years). The histological classification of the lung cancers was as follows: adenocarcinoma in 85 cases, squamous cell carcinoma in 42 cases, small-cell lung cancer in 32 cases, and large cell lung cancer in 7 cases. Bone metastasis was present in 73 of the 166 cases. PS was 0 in 17 cases, 1 in 86 cases, 2 in 30 cases, and $\geq$3 in 33 cases. According to the staging system (TNM Stage Ver. 6), there were 9 stage Ia–IIb cases, 11 stage IIIa cases, 45 stage IIIb cases, and 101 stage IV cases (Table 1).

The mean/median serum NTx values according to the presence/absence of bone metastasis were 27.8/23.8 nmol bone collagen equivalents (BCE)/L in the bone metastasis-positive group and 17.1/16.5 nmol BCE/L in the bone metastasis-negative group. The differences were significant ($P < 0.001$ for both groups).

The ROC curve plotted to determine the relationship between serum NTx values and bone metastasis revealed an optimal cutoff value of 22.0 nmol BCE/L and yielded a sensitivity of 61.6% and a specificity of 89.2%. We also plotted ROC curves for LDH and ALP. The values of these parameters are thought to increase in bone metastasis. These parameters were compared with the ROC curve for serum NTx. Compared to ALP and LDH levels, the serum NTx level was found to have a clearly superior correlation with bone metastasis (Fig. 1).

In this study, we performed a univariate analysis and multivariate analysis based on the optimal cutoff values (22.0 nmol BCE/L) of serum NTx on the ROC curves. The

Table 1 Patients characteristics ($n = 166$)

Age (years)	Median (range)	68 (23–85)
Sex	Males	128 (77.1%)
	Females	38 (22.9%)
Histological type	Squamous cell carcinoma	42 (25.3%)
	Adenocarcinoma	85 (51.2%)
	Small-cell carcinoma	32 (19.3%)
	Other tumor	7 (4.2%)
Stage	Ia–IIb	9 (5.4%)
	IIIa	11 (6.6%)
	IIIb	45 (27.1%)
	IV bone metastasis positive	73 (44.0%)
	IV bone metastasis negative	28 (16.9%)
Performance status (PS)	0	17 (10.2%)
	1	86 (51.8%)
	2	30 (18.1%)
	3	24 (14.5%)
	4	9 (5.4%)



Fig. 1 The optimal value was selected by a receiver operating characteristic (ROC) curve analysis of relationship between abnormal serum NTx values and bone metastasis of lung cancer and compared to ROC curve of ALP and LDH

parameters of the analysis were age, sex, PS, histological type, serum NTx value, CEA, CYF, NSE, Ca, ALP, and LDH.

The univariate analysis revealing albumin, LDH, and Ca tended to relate to bone metastasis. Furthermore, PS, ALP, and NTx were found to be significantly related to bone metastasis. It is especially noteworthy that the NTx values were closely associated with the presence or absence of bone metastasis from lung cancer ($P < 0.0001$) (Table 2). PS, albumin, ALP, LDH, Ca, and NTx were included in the multivariate analysis. The results showed that ALP tended to be associated with bone metastasis, and a particularly close association was found between serum NTx levels and bone metastasis from lung cancer ($P < 0.0001$) (Table 3).

Table 2 Univariate analysis in the bone metastasis-positive and bone metastasis-negative group

Bone metastasis from lung cancer	Negative (93)	Positive (73)	*P* value
Age			
≦70	60	39	0.581
70<	33	34	
Sex			
Males	74	54	0.395
Females	19	19	
Pathology			
Non-small-cell lung cancer	74	60	0.671
Small-cell lung cancer	19	13	
PS			
0, 1	67	36	**0.00114**
2, 3, 4	26	37	
Total protein			
≦6.6 [g/dL]	29	28	0.3346
6.6<	64	45	
Albumin			
≦3.4 [g/dL]	16	21	0.0782
3.4<	77	52	
CEA			
≦5 [ng/ml]	76	43	0.3786
5 < [ng/ml]	17	30	
NSE			
≦12 [ng/ml]	67	36	0.433
12<	26	39	
Cytokeratin 19 fragment			
≦3.5 [ng/ml]	16	20	0.7916
3.5<	72	52	
ALP			
≦359 [IU/L]	76	43	**0.00151**
359<	17	30	
LDH			
≦229 [IU/L]	63	40	0.0891
229<	30	33	
Ca			
≦10.2 [mg/dL]	92	68	0.0842
10.2<	1	5	
NTx			
<22.0 [nmol BCE/L]	82	28	**<0.0001**
22.0≦	11	45	

Discussion

The initial diagnosis of bone metastasis is usually made on the basis of the results of bone scintigraphy, but the use of this technique is limited because it is costly and has a high rate of false positives. Furthermore, it is inconvenient to require the use of radioactive substances. Thus, the development of a convenient and useful marker of bone metastasis is imperative. Izumi et al. evaluated bone metabolism markers, such as D-PYD, 1CTP, and NTx, and concluded that urinary NTx is the most useful biomarker for the detection of bone metastasis in patients with lung cancer [8].

The major collagen in bone is type I collagen, and it accounts for 90% of the organic chemical components of bone [9]. NTx is one of the degradation products of collagen, formed as a result of bone resorption. It is highly bone specific and reflects bone resorption by osteoclast-derived cathepsin K during physiological bone remodeling [10]. NTx is also produced under conditions such as bone metastasis by malignant tumors and reflects bone resorption by matrix metalloproteinase as well. When bone is

Table 3 Multivariate analysis in the bone metastasis-positive and bone metastasis-negative group

Bone metastasis from lung cancer	Negative	Positive	*P* value
PS			
0, 1	67	36	0.2274
2, 3, 4	26	37	
Albumin			
≦3.4 [g/dL]	16	21	0.7916
3.4<	77	52	
ALP			
≦359 [IU/L]	76	43	0.062
359<	17	30	
LDH			
≦229 [IU/L]	63	40	0.1761
229<	30	33	
Ca			
≦10.2 [mg/dL]	92	68	0.6943
10.2<	1	5	
NTx			
<22.0 [nmol BCE/L]	82	28	<0.0001
22.0≦	11	45	

resorbed, NTx is released into the blood and is subsequently excreted in the urine. A difference between urinary NTx levels and serum NTx levels is that urinary markers are usually impacted by fluctuations in metabolism to a greater extent than serum NTx because bone metabolism follows a pattern of being very active during the night and decreasing in the afternoon. Therefore, bone metabolism marker values are high at night and low during the day. Furthermore, the analysis of urinary NTx requires caution with regard to the timing of specimen collection because the specimen must be obtained during the first void of the morning [11, 12]. We therefore thought that serum NTx levels might be easier to evaluate for an indication of bone metastasis.

Many clinical studies in which urinary NTx levels were used as a marker have been reported in the past [13–15]; however, we were unable to find examples of studies of serum NTx. In our study, the results clearly indicate that serum NTx levels are more closely related to bone metastasis than to ALP or LDH, which have been said to become elevated during bone metastasis [16, 17].

The results of this study suggest that an appropriate cutoff value of serum NTx is 22.0 nmol BCE/L and that the analysis of serum NTx levels will provide a simple and effective diagnostic marker of bone metastasis from lung cancer.

Acknowledgments The authors wish to thank all the patients participated in this study.

Conflict of interest The authors have no financial arrangements or relationships with any individuals or organizations that could potentially influence this work.

References

1. Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal. 2004;34:827–32.
2. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–94.
3. Perez DJ, et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 1983;2:613–6.
4. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92.
5. Pecherstorfer M, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995;80:97–103.
6. Massidda B, et al. Usefulness of pyridinium crosslinks and CA 15–3 as markers in metastatic bone breast carcinoma. Anticancer Res. 1996;16:2221–3.
7. Lipton A, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem. 1993;39:614–8.
8. Izumi M, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer. 2001;91:1487–93.
9. Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab. 1984;58:110–20.
10. Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone. 2000;26:241–7.
11. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998;63:102–6.
12. Blumsohn A, et al. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab. 1994;79:730–5.
13. Lipton A, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193–201.
14. Coleman RE, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–35.
15. De Marinis F, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280–8.
16. Yun HK, et al. Laboratory evaluation of bone marrow metastasis: single institute study. Korean J Lab Med. 2007;27:96–101.
17. Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci. 1994;31:197–293.

Lung Cancer 75 (2012) 368–373

Contents lists available at SciVerse ScienceDirect

Lung Cancer

journal homepage: www.elsevier.com/locate/lungcan



Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens☆

Yoshihisa Shimada [a,*], Seiji Niho [a], Genichiro Ishii [b], Tomoyuki Hishida [a], Junji Yoshida [a], Mitsuyo Nishimura [a], Kiyotaka Yoh [a], Koichi Goto [a], Hironobu Ohmatsu [a], Yuichiro Ohe [a], Kanji Nagai [a]

[a] Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
[b] Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

ARTICLE INFO

Article history:
Received 21 April 2011
Received in revised form 19 August 2011
Accepted 20 August 2011

Keywords:
High-grade neuroendocrine carcinoma
Small cell carcinoma
Large cell neuroendocrine carcinoma
Chemotherapy
Chemoradiotherapy

ABSTRACT

Background: The overall clinicopathological features or the optimal therapy for large cell neuroendocrine carcinoma (LCNEC) have yet to be defined, because LCNEC has not been studied in the same depth as had small cell lung carcinoma (SCLC) in both clinical and biological standpoints. The aim of this study was to elucidate the clinical features of high-grade neuroendocrine carcinoma (HGNEC)-probable LCNEC diagnosed by biopsy, and compare therapeutic efficacy with patients with SCLC.
Methods: We retrospectively examined the chart of total of 25 patients who underwent chemotherapy or chemoradiotherapy as initial therapy for a histologic diagnosis of HGNEC-probable LCNEC, using biopsy samples and compared their data with those of 180 patients with SCLC. We analyzed their responses to chemotherapy and/or radiation therapy and survival outcomes.
Results: In 25 patients with HGNEC-probable LCNEC, 18 patients initially received chemotherapy (17 (94%) of whom received platinum-based chemotherapy) with an overall response rate (ORR) of 61%. The remaining 7 patients received chemoradiotherapy with an ORR of 86%, and 12 of the 25 patients who received second-line chemotherapy had an ORR of 17%. A total of 101 patients with SCLC who initially received chemotherapy had an ORR of 63%, and 79 patients who initially received chemoradiotherapy had an ORR of 98%, and 102 of the 180 patients who received second-line chemotherapy had an ORR of 45%. The 1-year overall survival rate for patients with stage IV HGNEC-probable LCNEC ($n = 13$) and those with ED-SCLC ($n = 80$) was 34% and 49%, respectively ($p = 0.84$).
Conclusion: The overall response rate to initial treatment and the survival outcomes of HGNEC-probable LCNEC were comparable to those of SCLC, but the effectiveness of second-line chemotherapy appeared to differ between the 2 groups.

© 2011 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Large cell neuroendocrine carcinoma (LCNEC) of the lung and small cell lung carcinoma (SCLC) are both now considered to be high-grade neuroendocrine carcinomas arising in the lung. Travis et al. [1] were the first to propose the term LCNEC in 1991, to describe cancer which exhibits neuroendocrine morphologic features such as rosette formation, organoid nesting, and palisading, large tumor cells (typically 3 times larger in diameter than a small resting lymphocyte) with a low nuclear/cytoplasmic ratio, numerous nucleoli, a high mitotic rate (>10 in 10 high-power fields), a large degree of necrosis, and immunohistochemical positive staining findings for 1 or more neuroendocrine markers [2]. The tumor cells of SCLC are round, oval, or spindle-shaped; usually less than the size of three small resting lymphocytes, and have scant cytoplasm, finely granular chromatin, and absent or inconspicuous nucleoli [2]. The morphologic features of LCNEC differ distinctly from those of SCLC by definition, however, distinguishing LCNEC from SCLC based on the tumor cell size and chromatin morphology may be difficult in some cases.

SCLC has poorer outcome, despite its marked chemosensitivity, enabling temporary remission in most SCLC patients because most tumors relapse after chemotherapy or chemoradiotherapy. The standard therapeutic strategy for SCLC has already been

☆ All work included in the manuscript was performed at the National Cancer Center Hospital East, Kashiwa, Chiba, Japan. The research was approved by the Institutional Review Board. No patient consent was required as the research was a retrospective chart review and no personally identifiable information is included in the manuscript.

* Corresponding author at: Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan.
Tel.: +81 0 4 7133 1111; fax: +81 0 4 7131 4724.
E-mail address: zenkyu@za3.so-net.ne.jp (Y. Shimada).

0169-5002/$ – see front matter © 2011 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.lungcan.2011.08.012

Table 1
Proposed criteria for diagnosis of pulmonary HGNEC-probable LCNEC using biopsy specimens.

1.	Solid tumor nesting without either acinar or squamous differentiation
2.	Moderate or marked cellular atypia
3.	Large cell size with low nuclear to cytoplasmic ratio or moderate to abundant eosinophilic cytoplasm
4.	Vesicular and/or coarsely granular nuclear chromatin
5.	Prominent nucleoli
6.	Positive immunostaining for one or more neuroendocrine markers (NCAM, chromogranin A, and synaptophysin)
7	Ki-67/MIB1 labeling index >40%

NCAM, neural cell adhesion molecule; HGNEC, high-grade neuroendocrine carcinoma; LCNEC, large cell neuroendocrine carcinoma.

established, and second-line chemotherapy has been recognized to be well-tolerated and effective in patients with chemotherapy-sensitive SCLC [3–7]. In contrast, the overall clinicopathological features or the standard treatment for LCNEC have yet to be defined, because LCNEC has not been studied in the same depth as had SCLC in both clinical and biological standpoints. Moreover, the incidence of the pre-therapeutic diagnosis of LCNEC in unresectable cases is unknown. Although obtaining a definitive diagnosis of LCNEC using small biopsy specimen is difficult, there is an urgent need to establish the diagnostic criteria for LCNEC. Therefore, instead of diagnosing LCNEC, we usually use the term "high-grade neuroendocrine carcinoma (HGNEC)-probable LCNEC" based on the proposed criteria (Table 1).

The aim of this study was to elucidate the clinical features of unresectable HGNEC-probable LCNEC (HG-pLCNEC) with those of SCLC, and compare their outcomes.

2. Patients and methods

2.1. Patient enrollment

From January 2002 through December 2009, we retrospectively examined the charts of total of 25 patients with a histologic diagnosis of HG-pLCNEC, using biopsy specimens. Diagnoses of HG-pLCNEC were all confirmed by pathological examination on biopsy specimens according to the modified criteria for the diagnosis of high-grade non-small cell neuroendocrine carcinoma using biopsy specimens proposed by Igawa et al. [8] (Table 1). All patients had undergone a minimum of 1 course of chemotherapy or chemoradiotherapy as initial therapy. Furthermore, the data of a total of 180 patients with histologically confirmed SCLC who had completed a minimum of 1 course of chemotherapy or chemoradiotherapy were examined as a control group. We used these criteria because the diagnostic criteria for LCNEC in the third edition of the World Health Organization (WHO) guidelines, which have been mainly established for cases of surgical specimens, and fulfilling the diagnostic criteria for LCNEC according to the WHO classification system is often difficult with biopsy specimens. We extracted the clinical data of patients from their medical records, all of whom had been given diagnoses of unresectable HG-pLCNEC or SCLC based on the results of pre-therapeutic evaluation including physical examination, chest radiography, computed tomography (CT) of the chest and abdomen, magnetic resonance imaging (MRI) of the brain, isotopic bone scan, and positron emission tomography (PET) or combined PET-CT. Their clinical disease staging was then reassessed according to the 7th edition of the International Union Against Cancer TNM classification system [9]. Data collection and analyses were approved by the institutional review board in December 2010, and the need to obtain informed consent from patients was waived due to the retrospective nature of the study.

2.2. Histopathology

We reviewed all the available pathology slides of biopsy specimens in this study. After fixing the specimens with 10% formalin and embedding them in paraffin, serial 4 μm sections were stained with hematoxylin–eosin (HE). The sections were reviewed by 2 observers (Y.S. and G.I.) and we classified HG-pLCNEC if they fulfilled all the relevant criteria as described above (Table 1). Immunohistochemical analysis was performed to confirm the neuroendocrine features of the specimens. Formalin-fixed paraffin sections were stained for a panel of neuroendocrine markers, including a polyclonal anti-chromogranin A antibody (Ventana, Arizona), anti-neural cell adhesion molecule (NCAM) antibody (Nippon Kayaku, Tokyo, Japan), and monoclonal anti-synaptophysin antibody (DAKO, Glostrup, Denmark). Immunohistochemically, neuroendocrine differentiation was considered to be positive if the tumor cells exhibited focal, patchy, or diffuse staining in the intracellular areas for one or more of these 3 antibodies. The anti-human Ki-67 antigen was identified by use of a monoclonal mouse anti-human Ki-67 (clone MIB1) antigen (DAKO, Glostrup, Denmark). Only nuclear immunostaining was considered to be positive. The labeling index of Ki-67/MIB1 in each tumor was estimated as a percentage of positive cells by counting from 100 to 1000 tumor cells.

2.3. Evaluation

Response criteria were evaluated according to the Response Evaluation Criteria for Solid Tumors (RECIST) guidelines [10]. Patients were evaluated to confirm disease progression or relapse by physical examination, chest radiography, and CT of the chest and abdomen. In some patients, we used PET-CT, MRI or bone scintigraphy to detect the extent of disease progression.

2.4. Statistical analysis

Survival curves were plotted according to the Kaplan–Meier method and compared using the log-rank test. Overall survival (OS) was measured from the first day of treatment to the date of death from any cause or the date on which the patient was last known to be alive. All tests were two-sided, and p-values less than 0.05 were considered to be represent statistically significant difference. We used Statview 5.0 software (SAS Institute Inc., Cary, NC) to perform statistical analysis.

3. Results

Overall, 25 patients were recognized to have tumors with histological characteristics consistent with HG-pLCNEC based on biopsy specimens. The typical microscopic appearances of the transbronchial biopsy specimens in the current study are shown in Fig. 1. The tumor cells showed a proliferation of polygonal cells, and a low nuclear–cytoplasmic ratio, with no differentiation of acinar or squamoid features (A). Positive immunostaining findings for NCAM antibody were observed (B), but findings for chromogranin A and synaptophysin were negative (data not shown). The diagnoses of 17 of 25 patients were obtained by transbronchial lung biopsy, and the diagnoses of the remaining 8 patients were obtained by CT-guided needle biopsy.

The characteristics of all the patients examined in this study are shown in Table 2. Among the 25 patients with HG-pLCNEC, the median age was 67 years (range 48–83 years), and 22 patients (88%) were men. Of the 25 patients, all (100%) were current or former smokers. Stage III B was noted in 7 patients (28%), and 13 patients (52%) had stage IV. In the patients with HG-pLCNEC, 18

Table 2
Patient characteristics.

Characteristics	Category	HGpL	%	SCLC	%
No. of patients		25		180	
Age	Median (range)	67 (48–83)		68 (28–84)	
Gender	Male	22	88	148	82
	Female	3	12	32	18
Smoking status	Ever	25	100	172	96
	Never	0	0	8	4
Clinical stage	I	0	0	2	1
	II	1	4	12	7
	IIIA	4	16	37	21
	IIIB	7	28	39	22
	IV	13	52	90	50
Initial therapy	CT	18	72	101	56
	CRT	7	28	79	44
Tumor marker					
NSE	Median (NL: <16 ng/ml) (range)	30 (10–273)		29 (3–585)	
ProGRP	median (NL: <46 pg/ml) (range)	234 (10–20,000)		488 (7–18,000)	

HGpL, high-grade neuroendocrine carcinoma probable large cell neuroendocrine carcinoma; SCLC, small cell lung carcinoma; CT, chemotherapy; CRT, chemoradiotherapy; NL, normal level; NSE, neuron-specific enolase; ProGRP, pro-gastrin-releasing peptide.

(72%) received chemotherapy, and 7 (28%) received chemoradiotherapy as initial treatment.

Among the 180 patients with SCLC, there were 99 patients with limited disease SCLC (LD-SCLC), and the number with extensive disease SCLC (ED-SCLC) was 81. The median age was 68 years (range 28–84 years), and 148 patients (82%) were men. Of 180 patients, 172 (96%) were current or former smokers. In the SCLC patients, 101 (56%) patients initially received chemotherapy, and 79 (44%) patients received chemoradiotherapy.

Of the 25 patients with HG-pLCNEC, 12 patients (48%) received second-line chemotherapy. The remaining 13 patients did not receive chemotherapy due to death from disease, adverse events caused by initial treatment, or no active treatment determination. Of the SCLC patients, 104 (58%) received second-line chemotherapy. A diagram of the tumor types and management in patients in this study is shown in Fig. 2.

Treatments and clinical response are summarized in Table 3. The regimens of initial treatment chemotherapies are listed in Table 3(a). Of 18 patients with HG-pLCNEC who initially received chemotherapy, 17 (94%) received platinum-based chemotherapy, and the 7 patients who had chemoradiotherapy received platinum-based chemotherapy and concurrent radiation of 45–60 Gy. Of the 101 patients with SCLC who underwent chemotherapy, the most frequently administered chemotherapy regimen was carboplatin and etoposide ($n=42$), and the second most frequent was cisplatin and etoposide ($n=23$).

Among the 18 patients with HG-pLCNEC initially receiving chemotherapy, 1 achieved a complete response (CR) and 10 achieved a partial response (PR), with an overall response rate (ORR) of 61% (Table 3(b)). One patient with CR and 4 patients with PR received cisplatin and irinotecan. There were 2 PRs observed in the patients treated with carboplatin and paclitaxel, and 1 PR was observed in each group of patients treated with either cisplatin and vinorelbine, cisplatin and docetaxel, cisplatin and amrubicin, or irinotecan alone. Among the 7 patients with HG-pLCNEC initially receiving initially chemoradiotherapy, 6 achieved PR, with an ORR of 86%. In the patients treated with cisplatin and vinorelbine, 3 PRs were observed while 2 PRs were observed in the patients treated with cisplatin and etoposide, and 1 patient achieved PR with carboplatin and etoposide.

Among the 101 patients with SCLC initially receiving chemotherapy, 2 achieved CR and 62 patients achieved PR, with an ORR of 63%. Among the 79 patients with SCLC initially receiving chemoradiotherapy 21 achieved CR and 56 patients achieved PR, with an ORR of 98%.

The regimens of second-line chemotherapies are listed in Table 3(c). The following chemotherapy regimens were used in 12 patients with HG-pLCNEC: amrubicin alone ($n=4$), docetaxel alone ($n=3$), cisplatin and irinotecan ($n=3$), carboplatin and etoposide ($n=1$), and cisplatin and irinotecan and etoposide ($n=1$). In 102 patients with SCLC who received second-line chemotherapy, the frequent administered chemotherapy regimen was cisplatin and irinotecan ($n=34$), and the second most frequently administered was amrubicin alone ($n=18$).

Among the 12 patients with HG-pLCNEC receiving second-line chemotherapy, 2 patients achieved PR, with an ORR of 17% (Table 3(d)). One patients achieved PR in each group of patients treated with cisplatin and irinotecan, and carboplatin and paclitaxel. Among the 102 patients with SCLC receiving second-line chemotherapy, 4 achieved CR and 41 patients achieved PR, with an ORR of 45%. These results indicate that the effectiveness of second-line chemotherapy appeared to differ between HG-pLCNEC and SCLC patients in the present study, but the difference was statistically not significant ($p=0.12$).

Fig. 3 shows the OS curves for the stage IV HG-pLCNEC and ED-SCLC groups. The 1-year OS rate for patients with stage IV HG-pLCNEC was 34%, and that for patients with ED-SCLC was 49%, with no statistically significant difference ($p=0.84$).

4. Discussion

We set out to determine the clinical features of HG-pLCNEC and other related tumors diagnosed by biopsy specimens and compare these with those of SCLC. We also examined the efficacy of chemotherapy or chemoradiotherapy between HG-pLCNEC and that of SCLC. Little is known about the optimal treatment strategy of LCNEC because most publications concerning LCNEC are based on surgical materials, with limited cohort data [11–13]. From a treatment point of view, it is imperative to establish the appropriate definitive diagnostic criteria based on the examination of biopsy or cytologic specimens, and then evaluate the efficacy of chemotherapy or chemoradiotherapy for those patients with unresectable tumors.

It is often difficult to diagnose LCNEC with small biopsy specimens, because of the possibility of crushed remnants of tissue artifacts due to insufficient specimen size, and some morphological overlap regarding cell size or nucleus size between SCLC and LCNEC [14]. In order to resolve this histological ambiguity in neuroendocrine carcinoma cases with regard to a diagnosis of LCNEC



Fig. 1. A biopsy specimen diagnosed as HGNEC-probable LCNEC. (A) The histological features of HGNEC-probable LCNEC are shown with hematoxylin–eosin (HE) staining. The tumor cells are large, with a proliferation of polygonal cells, and have a low nuclear–cytoplasmic ratio, with no differentiation of acinar and squamoid features (400×). (B) Positive staining for neural cell adhesion molecule (NCAM).



Fig. 2. The characteristics of patients enrolled in this study.



Fig. 3. Overall survival (OS) curve for stage IV HGNEC-probable LCNEC and ED-SCLC groups. The 1-year overall survival rate for patients with stage IV HGNEC-probable LCNEC was 34%, and that for patients with ED-SCLC was 49% ($p = 0.84$).

or SCLC, many researchers have performed immunohistochemistry or molecular analysis [15–18]. Hiroshima et al. reported that the frequencies of the expression of CD56, mASH1, TTF-1, and p16 were higher and that of NeuroD was lower in SCLC than in LCNEC in immunohistochemical analysis. The authors stated that LCNEC and SCLC are different morphologically, phenotypically, and genetically, although there are some overlapping features [15]. Nitadori et al. performed tissue microarray analysis of surgically resected LCNEC and SCLC specimens using 48 antibodies, and demonstrated that significant expression of CK7, CK18, E-cadherin, and β-catenin is more characteristic of LCNEC than of SCLC, suggesting that LCNEC and SCLC have a different biologic phenotype [17]. Ullmann et al. examined comparative genomic hybridization for LCNEC and SCLC, and reported that there were differences in the expression at 3q, 6p, 10q, 16q, and 17p [19]. On the other hand, Jones et al. demonstrated that cDNA microarrays gene expression profiles showed LCNEC was not differently clustered from SCLC, but different from large cell carcinoma or other NSCLC histology [20]. Although the clinicopathological features of LCNEC were similar to those of SCLC, and there is a histological ambiguity with regard to a diagnosis of LCNEC or SCLC, some biological behaviors of LCNEC were different from those of SCLC. Because there is actually the difficulty regarding the use of kinds of imuunohistochemical antibodies in daily practice, we have used the unique diagnostic criteria for HG-pLCNEC developed specifically for biopsy specimens by Igawa et al. [8]. However, lung cancer including LCNEC diagnosed by biopsy materials might not be representative of the whole tumor characteristics, particularly in heterogeneous cancers. Combinations with SCLC do occur, but such tumors are classified as combined variants of SCLC. Therefore, when using only biopsy materials for diagnosis, misdiagnosis may be unavoidable. The HG-pLCNECs examined in the present study might be mostly LCNECs and other related tumors, which included combined subtypes or other histological types, and excluded pure SCLC. This is one of the potential limitations of the present study.

To the best of our knowledge, there are few retrospective studies on the therapeutic efficacy of chemotherapy and/or radiation therapy for LCNEC [8,21,22], and this is the first study to examine

Table 3
Treatments and clinical response.

(a) Initial therapy and chemotherapy regimens

	HGpL	SCLC
No. of patients	25	180
Initial therapy		
Chemotherapy (%)	18 (72)	101 (56)
CDDP + CPT-11	8	21
CDDP + VNR	4	0
CBDCA + PTX	2	0
CBDCA + ETP	1	42
CDDP + DTX	1	0
CDDP + AMR	1	2
CPT-11	1	0
CDDP + ETP	0	23
Others	0	13
Chemoradiotherapy (%)	7 (28)	79 (44)
CDDP + VNR	3	0
CBDCA + ETP	2	5
CDDP + ETP	2	72
Others	0	2

(b) Clinical response after initial therapy

	HGpL (*n* = 25)		SCLC (*n* = 180)	
Initial therapy	Chemotherapy only	CRT	Chemotherapy only	CRT
No. of patients	18	7	101	79
CR	1	0	2	21
PR	10	6	62	56
SD	5	1	19	2
PD	2	0	12	0
NE	0	0	6	0
Response rate (%)	11/18 (61)	6/7 (86)	64/101 (63)	77/79 (98)

(c) Second-line chemotherapy regimens

	HGpL	SCLC
No. of patients	12	102
AMR	4	18
DTX	3	0
CDDP + CPT-11	3	34
CBDCA + ETP	1	12
CDDP + ETP + CPT-11	1	11
CDDP + ETP	0	10
Others	0	17

(d) Clinical response after second-line chemotherapy

Response	HGpL (*n* = 12)	SCLC (*n* = 102)	*p*-Value
CR	0	4	
PR	2	41	
SD	4	16	
PD	6	42	
NE	0	1	
Response rate (%)	2/12 (17)	45/102 (43)	0.12

HGpL, high-grade neuroendocrine carcinoma probable large cell neuroendocrine carcinoma; SCLC, small cell lung carcinoma; CDDP, cisplatin; CPT-11, irinotecan; VNR, vinorelbine; CBDCA, carboplatin; PTX, paclitaxel; ETP, etoposide; DTX, docetaxel; AMR, amrubicin; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; CRT, chemoradiotherapy.

second-line chemotherapeutic efficacy. In the current study, the majority of patients with HG-pLCNEC were predominantly men, smokers, with elevated NSE and ProGRP values. These resemble the clinical features of those of SCLC, similarly to several previous reports regarding the clinicopathological characteristics of LCNEC [11,12]. We obtained a response rate to initial chemotherapy of 61% and that to chemoradiotherapy of 86% in patients with HG-pLCNEC, which was similar to those of SCLC. The survival of patients with stage IV HG-pLCNEC was also similar to that of ED-SCLC patients. Considered together, these results suggest that there was no statistically significant difference in the initial treatment efficacy between the HG-pLCNEC and SCLC groups. Some authors have reported no statistically significant difference in survival outcome between LCNEC and SCLC [11,13], whereas the survival of patients with surgically resected LCNEC is reported to be intermediate between that of atypical carcinoid and SCLC [23]. Many authors reported that survival in LCNEC was poorer than that in stage-matched NSCLC, and adjuvant therapy might be effective in cases of early stage LCNEC [24–27].

The present study showed that the ORRs of second-line chemotherapy were 17% and 45% for patients with LCNEC and SCLC, respectively. In patients with SCLC, the prognosis at relapse is poor, and response to second-line chemotherapy correlates with response to first-line therapy and also to the interval between first-line chemotherapy and disease progression. Second-line chemotherapy has been recognized to be well-tolerated and effective, with an ORR of 15–88% in patients with chemotherapy-sensitive SCLC [3–7]. The present study suggested that chemotherapeutic efficacy in patients with HG-pLCNEC might be lower than in those with SCLC, even though the chemotherapeutic regimens were heterogeneous. The number of patients with HG-pLCNEC in this study was too small to draw any definite conclusion in terms of differing benefits of chemotherapy regimens for NSCLC and SCLC, or a possible difference in second-line chemotherapeutic sensitivity between LCNEC and SCLC. However, although LCNEC is categorized as a NSCLC, molecular findings in SCLC and LCNEC showed some differences but much overlap, and overall clinicopathological features and the initial treatment response of LCNEC in our study or several published articles suggest that these tumors would be better classified as a high-grade neuroendocrine tumor comparable with SCLC, suggesting that chemotherapies using an SCLC-based standard protocol might be effective and significantly improves the survival of patients with LCNEC compared with those using a NSCLC-based protocol [12,24,26].

In conclusion, these results, although limited, that the clinical efficacy of initial chemotherapy and/or radiation therapy for patients with HG-pLCNEC is similar to that of SCLC, and there might be a different sensitivity to second-line chemotherapy between HG-pLCNEC and SCLC. Improved diagnostic criteria, specifically developed for biopsy specimens, are needed to analyze the biological behavior of LCNEC. Moreover, prospective additional studies in a larger series are clearly mandatory to confirm our data, and the role of a therapy strategy with SCLC-based regimens deserves sensitivity to chemotherapeutic agents and the optimal treatment protocol.

Conflict of interest statement

The authors declare no potential conflicts of interest regarding this study.

Grant support

This study was supported in part by a Grant-in-Aid for Cancer Research (19-10) from the Ministry of Health, Labour, and Welfare of Japan and a Grant-in-Aid for the Third Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour, and Welfare of Japan.

Acknowledgements

The authors thank Roderick J. Turner and Professor J. Patrick Barron of the Department of International Medical Communications of Tokyo Medical University for reviewing the English manuscript.

References

[1] Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler Jr GB, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529–53.
[2] Travis William D. EB HKM-H. In: Harris Curtis C., editor. Pathology and genetics of tumors of the lung, pleura, thymus and heart; 2004.
[3] Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090–6.
[4] Ebi N, Kubota K, Nishiwaki Y, Hojo F, Matsumoto T, Kakinuma R, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997;27:166–9.
[5] Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401–6.
[6] Kubota K, Nishiwaki Y, Kakinuma R, Hojo F, Matsumoto T, Ohmatsu H, et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 1997;15:292–6.
[7] Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448–53.
[8] Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, et al. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer 2010;68:438–45.
[9] Leslie Sobin MG CW, editor. TNM classification of malignant tumors. 7th ed.; 2009.
[10] Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000;92:179–81.
[11] Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006;24:70–6.
[12] Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFR-beta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005;23:8774–85.
[13] Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124:285–92.
[14] Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between small cells and large cells in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001;116:466–72.
[15] Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006;19:1358–68.
[16] Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Ryuge S, et al. Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. Pathol Int 2010;60:71–7.
[17] Nitadori J, Ishii G, Tsuta K, Yokose T, Murata Y, Kodama T, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol 2006;125:682–92.
[18] Sun L, Sakurai S, Sano T, Hironaka M, Kawashima O, Nakajima T. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Pathol Int 2009;59:522–9.
[19] Ullmann R, Petzmann S, Sharma A, Cagle PT, Popper HH. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol 2001;32:1059–63.
[20] Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363:775–81.
[21] Kozuki T, Fujimoto N, Ueoka H, Kiura K, Fujiwara K, Shiomi K, et al. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol 2005;131:147–51.
[22] Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005;49:217–23.
[23] Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934–44.
[24] Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg 2009;138:446–53.
[25] Iyoda A, Hiroshima K, Moriya Y, Sekine Y, Shibuya K, Iizasa T, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg 2006;132:312–5.
[26] Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006;82:1802–7.
[27] Saji H, Tsuboi M, Matsubayashi J, Miyajima K, Shimada Y, Imai K, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs 2010;21:89–93.

Cancer Chemother Pharmacol
DOI 10.1007/s00280-011-1768-8

ORIGINAL ARTICLE

Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer

Yoshinori Makino · Noboru Yamamoto · Hitoshi Sato · Reiko Ando · Yasushi Goto · Chiharu Tanai · Hajime Asahina · Hiroshi Nokihara · Ikuo Sekine · Hideo Kunitoh · Yuichiro Ohe · Erika Sugiyama · Nobuaki Yokote · Tomohide Tamura · Hiroshi Yamamoto

Received: 2 June 2011 / Accepted: 14 October 2011
© Springer-Verlag 2011

Abstract
Purpose The pharmacokinetic (PK)–pharmacodynamic (PD) relationship of amrubicin and its active metabolite, amrubicinol, has only been evaluated using trough levels of these agents since the full PK profiles not yet been clarified so far. This study was performed to analyze the full PK profiles of amrubicin and amrubicinol and to evaluate their toxicity–PK relationships in Japanese patients.
Methods Amrubicin (35–40 mg/m^2) was administered to 21 lung cancer patients on days 1–3 every 3–4 weeks. Fourteen blood samples were obtained per patient over the course of 3 administration days. The plasma concentrations of amrubicin and amrubicinol were quantitated by HPLC, and the relationships between PK parameters of these compounds and hematological toxicities were evaluated.
Results The overall PK profiles of amrubicin and amrubicinol were well characterized using a 3-compartment model and a 1-compartment model with a first-order metabolic process, respectively. The major toxicities were hematological. The clearance of amrubicinol was significantly correlated with grade 4 neutropenia ($P = 0.01$). The percentage decreases in the neutrophil count, hemoglobin level and platelet count were well correlated with the amrubicinol AUC.
Conclusion The pharmacokinetic profiles of amrubicin and amrubicinol were clarified, and the subsequent PK–PD analyses indicate that the clearance of amrubicinol is the major determinant of neutropenia.

Keywords Amrubicin · Amrubicinol · PK–PD study · Myelosuppression · Blood cell destruction

Y. Makino (✉) · R. Ando · N. Yokote · H. Yamamoto
Department of Pharmacy, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
e-mail: ymakino@ncc.go.jp

N. Yamamoto · Y. Goto · C. Tanai · H. Asahina · H. Nokihara · I. Sekine · H. Kunitoh · Y. Ohe · T. Tamura
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

H. Sato · E. Sugiyama
Clinical and Molecular Pharmacokinetics/Pharmacodynamics, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Introduction

Amrubicin (AMR) and its active metabolite, amrubicinol (AMR-OH), markedly inhibit topoisomerase II activity and are effective against lung cancer [1]. AMR is approved in Japan for the treatment of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). In AMR monotherapy, AMR is administered at a dose of 35–45 mg/m^2/day on three consecutive days every 3–4 weeks. Six phase II studies for second-line or third-line AMR monotherapy for the treatment of SCLC have demonstrated overall response rates (ORRs) of 21–53% and a median survival period of 6–12 months [2–7]. Two phase II studies of previously treated NSCLC have been reported, with ORRs of 11.5 and 13.5%, respectively [5, 8]. In these phase II studies, the incidences of grade 3 or 4 myelosuppression were 82% (39–97%) [Median (Range)] for neutropenia, 28% (8–38%) for thrombocytopenia and 27% (5–41%) for anemia, respectively. Furthermore, the incidence of febrile neutropenia was 12% (2–35%).

The pharmacokinetic (PK)–pharmacodynamic (PD) profiles of AMR and AMR-OH have not yet been fully clarified so far. In a previous report by Matsunaga et al. [9],

Published online: 01 November 2011

full-sampling data were obtained from only one subject treated with 30 mg/m^2 of amrubicin and other data were obtained spars-sampling points from 15 patients (30–45 mg/m^2). On the other hand, significant relationships were observed between the plasma trough level of AMR-OH on day 4 and neutropenia and anemia [10]. The trough level of AMR-OH was correlated with the percent change in the neutrophil count [10]. However, the previous studies did not obtain plasma sampling points capable of fully characterizing the PK profiles of AMR and AMR-OH for consecutive days. Generally, the use of plasma drug concentration at only one particular time point should cause some uncertainty for establishing efficacy–PK or toxicity–PK relationships, and full PK profiling of a drug and subsequent modeling approach are highly preferable.

We, therefore, conducted a PK–PD study on AMR and AMR-OH in which we determined the PK model parameters of these agents throughout 3 days of administration and evaluated the toxicity–PK relationships in Japanese lung cancer patients based on the full PK profiles.

Materials and methods

Patients and treatments

This study was conducted at the National Cancer Center Hospital, Tokyo, Japan. Patients were eligible for participation in this study if they were 20 years or older and had been diagnosed as having lung cancer and had received AMR monotherapy. Patients with hepatitis B or C virus or human immunodeficiency virus infections and those who were considered by their physician to be ineligible as a trial candidate were excluded. Written informed consent was provided by each patient before study enrollment. The study was approved by the ethical review boards of the National Cancer Center Hospital and Showa University. It was conducted in accordance with the Declaration of Helsinki and all applicable laws and regulations.

AMR (Calsed™; Dainippon Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan) was dissolved in 50 mL of physiological saline and was administered intravenously as a 5-min infusion at a dose of 35–40 mg/m^2/day on days 1–3 every 3–4 weeks. For second- or later-line treatment of small or non-small-cell lung cancer with AMR, the recommended dose of AMR is 40 mg/m^2, in general, with some dose reduction (e.g., 35 mg/m^2) as needed based on the judgment of the attending physician. Prophylactic antiemetics (granisetron and dexamethasone) were used only as required and according to the physician's discretion. Other medications for underlying diseases, complications and pain control were allowed.

Before treatment, all patients underwent a medical history survey, physical and hematological examinations and serum biochemistry tests. The physical examination and biochemistry tests were repeated as part of normal clinical practice. The toxicities were graded according to the National Cancer Institute Common Toxicity Criteria, Version 3.0. Response was assessed according to the Response Evaluation Criteria in Solid Tumors [11].

Pharmacokinetic sampling and drug assays

PK evaluations were performed in all patients during the initial cycle of treatment. Heparinized venous blood samples (4 mL) were taken before infusion, at the end of the AMR infusion (0 min), as well as at 5, 15 and 30 min and 1, 2, 4, 8 and 24 h after the end of the infusion and at 0 min and 8 h after the infusions on days 2 and 3.

The plasma samples were stored at −80°C until analysis. The plasma concentrations of AMR and AMR-OH were measured using a previously reported high-performance liquid chromatography (HPLC) method [12]. The components were separated using HPLC on two reverse-phase columns linked with a connector (Onyx Monolithic C18, 100 × 4.6 mm) using 4 mM sodium 1-octanesulfonate, 2.3 mM acetic acid:tetrahydrofuran:dioxane (15:2:6, v/v/v) as an eluent. AMR and AMR-OH were measured using a fluorescence detector set at an excitation wavelength of 480 nm and a detection wavelength of 550 nm. Standard AMR and AMR-OH powders with purities >99% were supplied by Dainippon Sumitomo Pharmaceuticals Co., Ltd. (Osaka, Japan). The assay was validated according to the guidelines recommended by the U.S. Food and Drug Administration. The limit of quantitation was 2.5 ng/mL for both AMR and AMR-OH. The percentage recovery from the plasma proved to be higher than 88.1%. Intraday accuracy ranged from −4.1 to 0.8% for AMR and −9.8 to −2.1% for AMR-OH. The interday accuracy ranged from −3.1 to 3.0% for AMR and −4.0 to 2.3% for AMR-OH. The intraday precision ranged from 1.4 to 8.8% for AMR and 1.3 to 4.2% for AMR-OH. The interday precision ranged from 2.7 to 8.8% for AMR and 5.3 to 5.5% for AMR-OH.

Pharmacokinetic analysis

The PK parameters were estimated using a non-linear least-squares regression analysis (WinNonlin, Version 5.0.1; Pharsight, Cary, NC, USA) with a weighting factor of $1/Y^2$, where Y represents the observed data. The individual plasma concentration–time data were fitted to one-, two- or three-exponential equations using a constant infusion input for AMR and a one- or two-compartment model with a first-order metabolic process from AMR to AMR-OH

(parameterized by k_{in}). The PK model was optimized on the basis of Akaike's information criteria (AIC). Fitted parameters were permitted in the computation of the following PK parameters: AUC, peak plasma concentration of day 1 (C_{max}), total body clearance (CL) and volume of distribution at steady state (Vd_{ss}).

Pharmacodynamic analysis

The relationships between PK parameters (AUC and C_{max}) of AMR-OH and the hematologic toxicity were evaluated. The percentage decrease in the hematologic count or level (neutrophils and hemoglobin) was calculated as follows:

$$\%\,\text{Decrease in hematologic count or level} = \frac{\text{pretreatment count or level} - \text{nadir count or level}}{\text{pretreatment count or level}} \times 100$$

The results were plotted as a function of the AUC and C_{max} of AMR-OH, respectively. Relationships between adverse effects and PK exposure (AUC) or C_{max} were fitted using a non-linear least-squares regression and a weighting factor of unity according to a sigmoid model, as follows:

$$\text{Adverse effect}\ (\%\ ) = \frac{E_{max} \cdot \text{AUC}^{\gamma}}{\text{EC}_{50}{}^{\gamma} + \text{AUC}^{\gamma}} \times 100$$

or

$$\text{Adverse effect}\ (\%\ ) = \frac{E_{max} \cdot C_{max}{}^{\gamma}}{\text{EC}_{50}{}^{\gamma} + C_{max}{}^{\gamma}} \times 100$$

where E_{max} represents the maximum effect and EC_{50} is the AUC (or C_{max}) of AMR-OH at which the effect was 50% of the maximum effect. A non-linear least-squares regression was conducted using WinNonlin to estimate E_{max}, EC_{50} and the sigmoidicity coefficient (γ). The strength of the relationship between the percent decrease in the hemoglobin level and the AUC (or C_{max}) of AMR-OH was assessed using a least-squares linear regression analysis.

In the PD analysis, the patient characteristics as well as the PK parameters were compared among patients who experienced grade 4 neutropenia ($<500/\mu L$). The patient characteristics that were evaluated for possible association with grade 4 neutropenia were age, sex, performance status (0 vs. ≥ 1), type of disease (SCLC vs. NSCLC), smoking index, prior surgery, prior thoracic or brain irradiation, the number of prior chemotherapy regimens (1 vs. ≥ 2), albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), serum α_1-acid glycoprotein (AGP) and pretreatment neutrophil counts. PK parameters, including C_{max}, AUC and CL of AMR and AMR-OH, were also compared between patients who experienced and those who did not experience grade 4 neutropenia.

Statistical analyses

The obtained data were presented as mean ± standard deviation (SD). To identify factors associated with grade 4 neutropenia, continuous variables were compared between patients with and those without grade 4 neutropenia using the Mann–Whitney U-test, and differences in the distribution of dichotomized variables were evaluated using the χ^2-test or the Fisher exact test, as appropriate. $P < 0.05$ was considered statistically significant, and all P-values were two-tailed. To identify variables significantly associated with grade 4 neutropenia, multivariate logistic regression analyses were performed. All statistical analyses were performed using the statistical software JMP 4.0 (SAS Institute, Cary, NC, USA).

Results

Patient characteristics

Twenty-one patients were enrolled in this study from May 2007 to June 2009. The patient characteristics are listed in Table 1. Seventeen patients had SCLC, and 4 patients had NSCLC. Seventeen patients were men, and 4 were women; all patients had a good performance status, and the median age was 64 years. All 21 patients had previously undergone at least one chemotherapy regimen. All patients had received a platinum agent (cisplatin or carboplatin), and 20 patients had received some form of topoisomerase inhibitor (irinotecan, etoposide or topotecan). Only one patient who had been diagnosed as having squamous cell carcinoma had not been treated with a topoisomerase inhibitor. All patients were included in the PK and toxicity evaluations. Eighteen patients were assessed for response and survival. Two patients were not assessed for response because of the occurrence of interstitial pneumonia or a cardiac event after the second cycle; chemotherapy was discontinued in these patients. Another patient developed disseminated intravascular coagulation (DIC), and chemotherapy was ceased because of the presence of grade 4 thrombocytopenia despite an insufficient response during the first cycle. Seven patients had received granulocyte colony-stimulating factor during the first cycle. All 21 patients had received prophylactic antiemetics. Among these patients, 8 were treated with granisetron and dexamethasone and 13 were treated with granisetron only prior to treatment with AMR on 3 consecutive days.

Pharmacokinetics

Patients received AMR at a dose of 40 mg/m^2 except for one patient with squamous cell carcinoma who received a

Table 1 Patient characteristics

$n = 21$	n	Median	Range
Sex			
Male/female	17/4		
Age (y.o.)		64	39–81
Disease			
SCLC (LD/ED)	5/12		
NSCLC (LCNEC/SQ)	3/1		
PS			
0/1/2	10/10/1		
Smoking history			
±	2/19		
Smoking index		1,165	0–3,200
Pretreatment			
Surgery			
±	15/6		
Radiation			
±	11/10		
Thoracic	5		
Whole brain	6		
Other	1		
Chemotherapy			
0/1/2≤	0/16/5		
CDDP/CPT	11		
CBDCA/ETOP	8		
Others	12		
Characteristics			
Height (cm)		163.8	155–177.5
Body weight (kg)		57	36–74.95
Body surface area (m^2)		1.62	1.28–1.89
Serum creatinine (mg/dL)		0.8	0.6–1.5
Aspartate amino transferase, AST (IU/L)		24	15–111
Alanine transaminase, ALT (IU/L)		18	7–61
Total bilirubin (mg/dL)		0.4	0.3–1.5
Lactate dehydrogenase, LDH (U/L)		233	133–1,286
Serum albumin (g/dL)		3.9	2.5–4.6
α_1-Acid glycoprotein, AGP (mg/dL)[a]		103.5	50–292
White blood cell (×1,000/μL)		5.4	2.5–15.2
Hemoglobin (g/dL)		11.9	7.2–15.3
Platelet (×10,000/μL)		22.2	12.2–37.3
Absolute neutrophil count, ANC (×1,000/μL)		3.6	1.4–11.9

SCLC small-cell lung cancer, *LD* limited disease, *ED* extensive disease, *NSCLC* non-small-cell lung cancer, *LCNEC* large-cell neuroendocrine carcinoma, *SQ* squamous cell carcinoma, *PS* performance status, *CDDP* cisplatin, *CPT* irinotecan, *CBDCA* carboplatin, *ETOP* etoposide

[a] α_1-Acid glycoprotein (AGP) data were obtained from 18 patients

dose of 35 mg/m^2 based on the judgment of the attending physician. Together, the patients received a total of 71 cycles (median of 4 cycles [range, 1–7]) of therapy. A total of 294 plasma samples were obtained for the PK analyses. The PK profiles for AMR and AMR-OH were well characterized using a 3-compartment model and a 1-compartment model with a first-order metabolic process from AMR to AMR-OH, respectively (Fig. 1). The plasma dispositions of AMR and AMR-OH, to which the PK models were fitted, are shown in Fig. 2, and the pharmacokinetic parameters are listed in Table 2.

The plasma concentrations of AMR decreased sharply shortly after the drug infusion and then slowly declined as a result of drug elimination and distribution into the peripheral and blood compartments. The infusion of AMR was followed 2 h later (t_{max}) by the peak plasma concentration of AMR-OH (C_{max}: 23 ± 7 μg/L; Fig. 2; Table 2). In two patients, AMR was metabolized rapidly to AMR-OH, leading to the generation of a large variation in the metabolic rate constant (k_{in}).

Toxicities

Grade 3/4 hematological toxicities consisted of neutropenia (81%), thrombocytopenia (33%) and anemia (19%). The most frequent grade 4 hematological toxicity, observed in 13 patients (62%), was neutropenia. The mean percentages of the decrease in the white blood cell count, absolute neutrophil count, platelet count and hemoglobin level for all 21 patients were 71 ± 20%, 85 ± 21%, 56 ± 29% and 16 ± 7%, respectively. All non-hematological toxicities were mild (≤grade 2). Three patients (14%) experienced febrile neutropenia. Dose reduction was required in 32% (6/19) of the patients, and a treatment delay (4 weeks or more) was needed in 12 patients because of prolonged hematological toxicity during the second cycle.

Responses

One patient with SCLC had a complete response, 8 patients had partial responses (SCLC 6, large-cell neuroendocrine carcinoma 2), 4 patients had stable disease (SCLC) and 5 patients had progressive disease (SCLC 4, squamous 1).

PK–PD relationship for hematologic toxicity

The present PK–PD analyses demonstrated that the percentage decrease in the absolute neutrophil count was related to the AUC and C_{max} of AMR-OH, as described by the sigmoid maximum effect (E_{max}) model. The plot in Fig. 3a and b depicts the E_{max} relationship using the data obtained from all patients. On the basis of the E_{max} model



Fig. 1 Schematic illustration of pharmacokinetic model for amrubicin and amrubicinol. The model includes three compartments for amrubicin and one for amrubicinol: k_{12}, k_{21}, k_{13} and k_{31} represent the rate constants for the intercompartmental transfers of AMR. k_{in} represents the metabolic conversion rate constant from AMR to AMR-OH. k_{el} represents the elimination rate constant for AMR-OH



Fig. 2 Concentrations in plasma versus time curves of AMR and AMR-OH. Plasma concentration–time profiles for AMR (*filled square*) and AMR-OH (*filled circle*). *Squares* or *circles* and vertical bars, mean measured concentration ± SD; lines, best-fit lines from the pharmacokinetic analysis (*solid lines* for AMR and *dashed lines* for AMR-OH)

fitting, the AUC and C_{max} that yielded a 50% decrease in the absolute neutrophil count were predicted to be 306.1 h μg/L and 13.2 μg/L, respectively. The shapes of the curves were steep ($\gamma = 8.4$ for AUC; $\gamma = 7.7$ for C_{max}), and these models provided a correlation between the PK of AMR-OH and neutropenia ($r = 0.8296$ for AUC; $r = 0.8035$ for C_{max}). A least-squares linear regression analysis showed that the percent decrease in the hemoglobin level could be estimated by the AUC and C_{max} of AMR-OH ($r = 0.6554$ for AUC; $r = 0.7267$ for C_{max}) (Fig. 3c, d). The AUC and C_{max} that yielded a 50% decrease in the platelet count were predicted to be 549.4 h μg/L and 22.1 μg/L, respectively. The shapes of the curves were gentle ($\gamma = 2.0$ for AUC; $\gamma = 1.9$ for C_{max}), and these models provided the correlation between the PK of AMR-OH and thrombocytopenia ($r = 0.679$ for AUC; $r = 0.6301$ for C_{max}) (Fig. 3e, f). When the characteristics of patients who experienced or did not experience grade 4 neutropenia were compared, the distribution of the performance status was significantly different, and the pretreatment body weight in patients with grade 4 neutropenia was significantly lower than in those without

Table 2 Pharmacokinetic parameters of AMR and AMR-OH

PK parameter	NCA		Model (single dose)[a]		Model (multiple dose)[b]	
	Mean	SD	Mean	SD	Mean	SD
AMR (NCA; constant infusion, Model; 3-compartment infusion)						
AUC (h μg/L)	3,218	684.6	3,175	730.7	3091	579
CL (L/h)	20.6	5.1	20.1	5	21.0	4.4
C_{max} (μg/L)	4,355	1,308	5,500	3,734	4,200	1,149
Vd_{ss} (L)	71.5	15.9	73	17.1	74.0	16.8
k_{12} (1/hr)	–	–	8.0	3.0	6.4	3.5
k_{13} (1/hr)	–	–	2.0	2.7	1.0	2.1
k_{21} (1/hr)	–	–	2.4	1.8	2.4	2.5
k_{31} (1/h)	–	–	0.4	0.2	0.4	0.2
AMR-OH (NCA; extravascular, model; 1-compartment with first-order metabolism)						
k_{in} (1/h)	–	–	12.7	32.3	2.3	2.0
AUC (h μg/L)	515	146	506.9	140.1	459.5	122.3
CL (L/h)	134.3	48.2	135.3	44.9	150.0	53.9
C_{max} (μg/L)	22.5	6.7	22.2	6.6	23.1	6.7
Vd_{ss} (L)	2,899	1,083	2,935	1,223	2,708	1,042

NCA non-compartmental analysis

[a] Model analysis using 9 plasma sampling points (0, 5, 15 and 30 min, and 1, 2, 4, 8 and 24 h after the end of infusion) after AMR infusion on day 1

[b] Model analysis using all plasma sampling points (0, 5, 15 and 30 min and 1, 2, 4, 8 and 24 h after the end of infusion on day 1 and 0 min and 8 h after the end of infusion on days 2 and 3) after AMR infusion on days 1–3

(Table 3). Among the PK parameters, the CL of AMR-OH and the Vd_{ss} of AMR were significantly lower in patients with grade 4 neutropenia.

On the other hand, in the present multivariate analysis, none of the parameters were identified as significant variables of grade 4 neutropenia.

Discussion

The intrinsic activity of the metabolite of AMR, AMR-OH, has been known to be 10–100 times higher than that of AMR [13].

The aims of the present study were to determine the PK parameters of AMR and AMR-OH and to clarify the relationships between PK parameters and toxicity associated with AMR therapy. For this purpose, we carried out an extensive PK–PD study on AMR and AMR-OH in 21 patients with lung cancer, where a total of 14 blood sampling per patient was accomplished over the course of 3 intravenous AMR administration days.

The PK profiles of AMR and AMR-OH were well characterized using a 3-compartment model with a short infusion and a 1-compartment model with a first-order metabolic process from AMR to AMR-OH, respectively. All PK model parameters of AMR and AMR-OH over the 3 administration days could be well extrapolated using the compartment model parameters obtained from a 24-h single-dose and non-compartmental analysis. The PK profiles for AMR and AMR-OH did not show non-linearity or accumulation. Therefore, the 3-day PK profile can be simulated using the plasma trough level observed on the first administration day, enabling the doses on days 2 and 3 to be adjusted, if necessary.

Using the compartment analysis, we were able to perform a kinetic approach to identifying the mechanisms responsible for the metabolism of AMR to AMR-OH and the subsequent metabolic pathway, thereby enabling a quantitative correlation between the PK and the hematological toxicities arising from AMR therapy. The AMR-OH clearance is an apparent clearance, since the percentage of AMR metabolized into AMR-OH is unknown and subject to interindividual variability.

In the present PK–PD study, it was found that a higher C_{max} and AUC of AMR-OH in the plasma was associated with a risk of grade 4 neutropenia and the percentage decrease in the absolute neutrophil count, as well as with the decrease in the platelet count. On the other hand, both parameters were well correlated with a linear model of the percentage decrease in the hemoglobin level. AMR is a quinone-containing anthracycline agent. Doxorubicin has a similar quinone structure and is known to reduce its respective semiquinone-free radicals in the presence of flavoenzymes. Free radicals can also be formed from the



Fig. 3 PK–PD correlation between hematological toxicity and AMR-OH PK parameters. Relationship between the percent decrease in the neutrophil, hemoglobin or platelet count and the AUC or C_{max} of AMR-OH; The solid lines indicate the best fit of a sigmoid E_{max} pharmacodynamic model to the data [neutrophil, AUC: (**a**), C_{max}: (**b**), platelet, AUC: (**e**), C_{max}: (**f**)]. The *solid line* is the linear regression line, and the *dashed line* is the 95% CI for individual estimates [hemoglobin, AUC: (**c**), C_{max}: (**d**)]

interaction of doxorubicin with iron to form a doxorubicin-iron III complex. The in vitro data indicated that dexrazoxane, which prevents anthracycline-mediated cardiotoxicity, inhibited the binding of doxorubicin to red blood cells but had no effect on the association of doxorubicin with erythrocyte ghosts [14]. These findings and a previous report describing an interaction between anthracyclines and iron or hemoglobin support our notion that the third compartment of the parental compound corresponds to the blood cells and that AMR-OH was converted from AMR in the blood, forming an AMR-OH-iron III complex that may directly destroy blood cells. Therefore, the cause of the severe hematological toxicities of AMR may be related not only to myelosuppression but also to the destruction of blood cells.

In multivariate analysis, we could not find the pretreatment factors or PK parameters to predict the severe neutropenia, possibly because the sample size was too small. On the other hand, body weight was found to be positively correlated with the Vd_{ss} of AMR. Moreover, the low Vd_{ss} of AMR was significantly correlated with the high AUC of AMR-OH, suggesting that patients with the low Vd_{ss} of AMR rapidly metabolized AMR to AMR-OH; as a result, hematological toxicities tended to be serious to such patients.

AMR was metabolized rapidly to AMR-OH in 2 patients, leading to the generation of large variations in the metabolic rate constant (k_{in}). The AMR-OH concentrations at the end of infusion in these patients were 29.9 and 11.0 ng/mL, far above the average AMR-OH concentration at the corresponding time point. Other PK parameters and their variations were similar between the single-dose and multiple-dose studies. When these data were excluded, the k_{in} in the single-dose study was determined to be 2.8 ± 0.5 (mean ± SD), which is close to the k_{in} value determined in the multiple-dose study.

The major pathway of AMR metabolism involves the reduction in the C-13 carbonyl group to a hydroxyl group

Table 3 Characteristics and pharmacokinetics of AMR and AMR-OH in patients with or without grade 4 neutropenia

Neutropenia	Neutrophils ≥ 500/μL	Neutrophils < 500/μL	*P* value
Patients (*n*)	8	13	
Sex (*n*)			0.13
Female	0	4	
Male	8	9	
Performance status (n)			0.001
0	8	3	
≥1	0	10	
Number of prior chemotherapy regimens (*n*)			0.33
1	5	11	
≥2	3	2	
Age (years)			1.00
Median	65	64	
Range	39–76	42–81	
Body weight			0.02
Median	65	53	
Range	55–75	36–72	
Serum creatinine			0.11
Median	0.9	0.8	
Range	0.7–1.5	0.0–1.1	
Total bilirubin			0.19
Median	0.4	0.6	
Range	0.3–0.6	0.3–1.5	
Aspartate amino transferase, AST			0.25
Median	23	26	
Range	15–32	16–111	
Serum albumin			0.08
Median	4.1	3.8	
Range	3.5–4.4	2.5–4.6	
AMR clearance, AMR-CL (L/h)			0.06
Median	21.9	18.5	
Range	18.8–33.8	11.7–24.4	
AMR distribution, Volume at steady state, Vd_{ss} (L)			0.02
Median	79.2	63.2	
Range	64.5–116.9	45.7–87.6	
AMR-OH clearance, AMR-OH-CL (L/h)			0.01
Median	167.0	105.9	
Range	86.8–278.4	77.6–149.8	

Sex, performance status and number of prior chemotherapy regimens were analyzed using the χ^2-test or the Fisher exact test. Others were analyzed using the Mann–Whitney *U*-test

by carbonyl reductase (CBR). Then, AMR and AMR-OH are inactivated by NAD (P) H: quinone oxide reductase (NQO) and NADPH P-450 reductase [15].

Genetic polymorphisms of these metabolic enzymes are reportedly related to the PK of several anticancer agents [16–18]. CBR-1 D2 diplotypes tagged by at least one variant allele at the CBR-1 c.627C > T and +967G > A loci are correlated with significantly higher exposure levels of doxorubicin, suggesting the possibility that the intracellular conversion to doxorubicinol is reduced in Asian patients with breast cancer [15]. In another investigation, the NQO-1 609 C > T polymorphism resulted in a significantly reduced tumor NQO-1 activity and a reduced survival in subsets of patients receiving intraperitoneal hyperthermic mitomycin C [18]. However, the exact reason for interindividual variations in the PK of AMR remains unknown; thus, the relationship between genetic polymorphisms of metabolic enzymes and transporters for AMR and AMR-OH should be evaluated in the future.

In this study, several types of lung cancer patients were enrolled (including 17 patients with SCLC, 3 with large-cell neuroendocrine carcinomas and 1 with squamous cell carcinoma). Furthermore, among 17 patients with SCLC, five subjects had limited disease and 12 had extensive disease. These variations of the tumor properties inevitably led to a limitation of this study, i.e., the difficulty in clarifying the PK–PD relationship between the AUC of AMR/AMR-OH and the tumor response.

In conclusion, we clarified the full PK profiles of AMR and AMR-OH and found that the CL of AMR-OH is the major determinant of neutropenia. PK–PD evidence has not yet been reported for this compound on a global basis so far, since AMR is approved only in Japan. Thus, the present findings should be of great importance for avoiding or reducing severe hematological toxicities associated with AMR therapy. In order to confirm our findings and to identify factors influencing the interindividual variabilities in the PK–PD parameters for AMR, further population PK studies and pharmacogenetic studies on a larger number of patients are highly warranted.

Acknowledgments This work was supported in part by the Foundation for the Promotion of Cancer Research in Japan.

References

1. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229–1238
2. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K (2006) Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24:5448–5453
3. Kato T, Nokihara H, Ohe Y, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Nishiwaki Y, Saijo N, Tamura T (2006) Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC) J Clin Oncol, ASCO Annual Meeting Proceedings Part I, (18S):7061

4. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401–5406
5. Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, Yoshii A, Fueki N, Hisada T, Ishizuka T, Saito R, Mori M (2010) A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 69:99–104
6. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW (2010) Phase II study of Amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28:2598–2603
7. Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF, Oliver JW (2011) Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29:287–293
8. Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, Kimura T, Sugiura T, Sawa T, Takeda K, Iwamoto Y, Satouchi M, Akita K, Saito H, Goto I, Shibata K, Fukuoka M, Nakagawa K (2010) Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). J Thorac Oncol 5:105–109
9. Matsunaga Y, Hamada A, Okamoto I, Sasaki J, Moriyama E, Kishi H, Matsumoto M, Hira A, Watanabe H, Saito H (2006) Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit 28:76–82
10. Kimura T, Kudoh S, Mitsuoka S, Yoshimura N, Tanaka H, Asai K, Kyoh S, Tochino Y, Umekawa K, Hirata K (2009) Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities. Anticancer Drugs 20:513–518
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
12. Ando R, Makino Y, Tamura T, Yamamoto N, Nishigaki R, Kimura T, Yokote N, Yamamoto H (2010) Simple and sensitive HPLC method for determination of amrubicin and amrubicinol in human plasma: application to a clinical pharmacokinetic study. Biomed Chromatogr 24:301–306
13. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067–1073
14. Vaidyanathan S, Boroujerdi M (2000) Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. Cancer Chemother Pharmacol 46:93–100
15. Tani N, Yabuki M, Komuro S, Kanamaru H (2005) Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica 35:1121–1133
16. Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:2045–2054
17. Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC (2008) Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 18:621–631
18. Fleming RA, Drees J, Loggie BW, Russell GB, Geisinger KR, Morris RT, Sachs D, McQuellon RP (2002) Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics 12:31–37